Given the ability of VVL-21 to induce significant intratumoral effector CD8+ T cell responses, but its inability to exert long-term control over tumor growth, we investigated whether incorporation of a monoclonal antibody to PD-1 was able to enhance the antitumor efficacy of the regime. The gene discussed is PDCD1; the disease is neoplasm.